Medtech innovator Xyall attracts €6M Series B funding to further expand its molecular pathology solutions and make them available to the market on a larger scale. The funding comes from existing investors such as the Brabant Development Agency (BOM) and Sioux Technologies, a consortium led by Health Investment Partners (HIP) and several private investors. Read more
